Literature DB >> 12913923

The predictive value of anti-cyclic citrullinated peptide antibodies in early arthritis.

Louise M A Jansen1, Dirkjan van Schaardenburg, Irene van der Horst-Bruinsma, Rob J van der Stadt, Margret H M T de Koning, Ben A C Dijkmans.   

Abstract

OBJECTIVE: To assess the additional predictive value of anti-cyclic citrullinated peptide (anti-CCP) antibodies above conventional variables for progressive erosive or disabling disease in a cohort of patients with early inflammatory oligo- and polyarthritis. Methods. Consecutive new patients with peripheral arthritis of > 2 joints and < 2 years of symptom duration, referred between 1995 and 1999 were studied. Excluded were patients with bacterial, psoriatic, crystal-induced arthritis or spondyloarthropathy. Optimal cut-off values for serum IgM-rheumatoid factor (RF) and anti-CCP were deduced from receiver operating characteristics curves. At 2 year followup, progressive erosive disease was defined as: radiographic progression > 5 (Sharp-van der Heijde units) and low functional capacity as a Health Assessment Questionnaire score > 1. For the statistical analysis, a logistic regression model was used.
RESULTS: A total of 282 patients [68% female, median age 56 yrs (18-83)] were included. Thirty-two percent of the patients were positive for anti-CCP at baseline. Anti-CCP correlated significantly (p < 0.001) with a progressive erosive disease after 2 years, but not with a low functional capacity. The combination of a positive anti-CCP status and radiographic damage at baseline could predict the radiographic progression with a sensitivity, specificity, and accuracy of 78%, 82%, and 81%, respectively. The positive predictive value (PPV) for radiographic progressive disease was 63%, while the negative predictive value (NPV) was 90%. The accuracy of the model decreased from 81 to 76% after leaving out anti-CCP from the model. In a subgroup of 178 IgM-RF negative patients, the PPV for radiographic progressive disease was 40%, while the NPV was 95%.
CONCLUSION: Anti-CCP positivity has a small additional value above the conventional prognostic variables for progressive erosive disease in a cohort of patients with early inflammatory oligo- and polyarthritis. The prognostic value of anti-CCP lies mainly in its ability to predict mild disease. This effect is accentuated in the subgroup of IgM-RF negative patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12913923

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  39 in total

1.  Generalized bone loss as a predictor of three-year radiographic damage in African American patients with recent-onset rheumatoid arthritis.

Authors:  Jie Zhang; David T Redden; Gerald McGwin; Leigh F Callahan; Edwin A Smith; Graciela S Alarcón; Larry W Moreland; Désirée M van der Heijde; Elizabeth E Brown; Donna K Arnett; Ted R Mikuls; S Louis Bridges
Journal:  Arthritis Rheum       Date:  2010-08

Review 2.  Anti-citrullinated peptide antibody assays and their role in the diagnosis of rheumatoid arthritis.

Authors:  Rohit Aggarwal; Katherine Liao; Raj Nair; Sarah Ringold; Karen H Costenbader
Journal:  Arthritis Rheum       Date:  2009-11-15

Review 3.  Anti-citrullinated peptide antibodies and their value for predicting responses to biologic agents: a review.

Authors:  Emilio Martin-Mola; Alejandro Balsa; Rosario García-Vicuna; Juan Gómez-Reino; Miguel Angel González-Gay; Raimon Sanmartí; Estíbaliz Loza
Journal:  Rheumatol Int       Date:  2016-06-06       Impact factor: 2.631

Review 4.  Cellular and molecular perspectives in rheumatoid arthritis.

Authors:  Douglas J Veale; Carl Orr; Ursula Fearon
Journal:  Semin Immunopathol       Date:  2017-05-15       Impact factor: 9.623

5.  Accumulation of plasma cells expressing CXCR3 in the synovial sublining regions of early rheumatoid arthritis in association with production of Mig/CXCL9 by synovial fibroblasts.

Authors:  T Tsubaki; S Takegawa; H Hanamoto; N Arita; J Kamogawa; H Yamamoto; N Takubo; S Nakata; K Yamada; S Yamamoto; O Yoshie; M Nose
Journal:  Clin Exp Immunol       Date:  2005-08       Impact factor: 4.330

6.  Cost-effectiveness of adding magnetic resonance imaging to rheumatoid arthritis management.

Authors:  Lisa G Suter; Liana Fraenkel; R Scott Braithwaite
Journal:  Arch Intern Med       Date:  2011-04-11

7.  Anti-CCP antibodies in rheumatoid arthritis and psoriatic arthritis.

Authors:  N Inanc; E Dalkilic; S Kamali; E Kasapoglu-Günal; Y Elbir; H Direskeneli; M Inanc
Journal:  Clin Rheumatol       Date:  2006-03-15       Impact factor: 2.980

8.  [Is the treatment response in elderly patients with rheumatoid arthritis diminished? Results of a prospective study over 3 months].

Authors:  C Fiehn; S Kessler
Journal:  Z Rheumatol       Date:  2009-02       Impact factor: 1.372

9.  Anti-cyclic citrullinated peptide, rheumatoid factor, and ocular symptoms typical of rheumatoid arthritis.

Authors:  Sujit Itty; Jose S Pulido; Sophie J Bakri; Keith H Baratz; Eric L Matteson; David O Hodge
Journal:  Trans Am Ophthalmol Soc       Date:  2008

10.  Autoantibodies to cyclic citrullinated peptide 2 (CCP2) are superior to other potential diagnostic biomarkers for predicting rheumatoid arthritis in early undifferentiated arthritis.

Authors:  Eriko Kudo-Tanaka; Shiro Ohshima; Masaru Ishii; Toru Mima; Masato Matsushita; Naoto Azuma; Yoshinori Harada; Yoshinori Katada; Hitomi Ikeue; Mitsuko Umeshita-Sasai; Kunio Miyatake; Yukihiko Saeki
Journal:  Clin Rheumatol       Date:  2007-02-08       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.